Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ozempic (semaglutide)
Biotech
Lilly's oral GLP-1 delivers Ozempic-like efficacy in phase 3
The phase 3 study linked the oral GLP-1 drug orforglipron to similar reductions in blood glucose and body weight to Novo's injectable blockbuster.
Nick Paul Taylor
Apr 17, 2025 6:45am
Obesity biotech Metsera files for a swift IPO
Jan 11, 2025 9:05am
Chinese insulin maker’s GLP-1 bests Ozempic in ph. 2, company says
Oct 15, 2024 11:12am
UPDATE: Lilly-backed metabolic disease biotech files IPO
Sep 4, 2024 10:23am
GLP-1 liraglutide reduces cognitive decline in Alzheimer's
Jul 30, 2024 1:29pm
A look at the R&D landscape in obesity, led by GLP-1s
Mar 19, 2024 8:00am
